The purpose of this announcement is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 SGB V. The invitation to participate is only addressed to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act. This is not an open procedure pursuant to Section 15 VgV in conjunction with Section 119 (3) ARC, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act can become contractual partners.
Alendronsäure, Colecalciferol (ATC-Code: M05BB03) Darreichungsform: TABThe purpose of this announcement is to conclude agreements on the active ingredient "alendronic acid, colecalciferol (ATC code: M05BB03) dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Calciumcarbonat, Colecalciferol (ATC-Code: A12AX) Darreichungsform: BTA, FTA, KTA, BrausegranulatThe purpose of this announcement is to conclude agreements on the active ingredient "calcium carbonate, colecalciferol (ATC code: A12AX) dosage form: BTA, FTA, KTA, EFFERVESCENT GRANULES" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Clopidogrel, Acetylsalicylsäure (ATC-Code: B01AC30) Darreichungsform: FTAThe purpose of this announcement is to conclude agreements on the active ingredient "clopidogrel, acetylsalicylic acid (ATC code: B01AC30) dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Colistimethate sodium (ATC code: J01XB01)The purpose of this announcement is to conclude agreements on the active ingredient "Colistimethat natrium (ATC code: J01XB01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Cyanocobalamin - apothekenpflichtig (ATC-Code: B03BA01) Darreichungsform: FTA, UTAThe purpose of this announcement is to conclude agreements on the active ingredient "Cyanocobalamin - pharmacy-only (ATC code: B03BA01) dosage form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Cyproteron acetat, Ethinylestradiol (ATC-Code: G03HB01) Darreichungsform: FTA, UTAThe purpose of this announcement is to conclude agreements on the active ingredient "cyproterone acetate, ethinyl estradiol (ATC code: G03HB01) dosage form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Desogestrel, Ethinylestradiol (ATC-Code: G03AA09) Darreichungsform: FTA, TABThe purpose of this announcement is to conclude agreements on the active ingredient "desogestrel, ethinyl estradiol (ATC code: G03AA09) dosage form: FTA, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Drospirenon, Ethinylestradiol (ATC-Code: G03AA12) Darreichungsform: FTAThe purpose of this announcement is to conclude agreements on the active ingredient "drospirenone, ethinyl estradiol (ATC code: G03AA12) dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Drospirenon (ATC-Code: G03AC10) Darreichungsform: FTAThe purpose of this announcement is to conclude agreements on the active ingredient "drospirenone (ATC code: G03AC10) dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Estriol (ATC-Code: G03CA04) Darreichungsform: VCRThe purpose of this announcement is to conclude agreements on the active ingredient "Estriol (ATC code: G03CA04) dosage form: VCR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
famotidine (ATC Code: A02BA03)The purpose of this announcement is to conclude agreements on the active ingredient "famotidine (ATC code: A02BA03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ambroxol - apothekenpflichtig (ATC-Code: R05CB06) Darreichungsform: LOE, LSE, SAF, SIR, TRO, Tropflösung, TEIThe purpose of this announcement is to conclude agreements on the active ingredient "Ambroxol - pharmacy-only (ATC code: R05CB06) dosage form: LOE, LSE, SAF, SIR, TRO, drip solution, TEI" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Fluorouracil - against warts, salicylic acid (ATC CODE: L01BC52)The purpose of this announcement is to conclude agreements on the active ingredient "Fluorouracil - against warts, salicylic acid (ATC code: L01BC52)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Flupentixol (ATC-Code: N05AF01) Darreichungsform: ILOThe purpose of this announcement is to conclude agreements on the active ingredient "Flupentixol (ATC code: N05AF01) dosage form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
gefitinib (ATC Code: L01EB01)The purpose of this announcement is to conclude agreements on the active ingredient "gefitinib (ATC code: L01EB01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ibuprofen (ATC-Code: M01AE01) Darreichungsform: REK, RET, Retardfilmtablette, SL- RetardkapselThe purpose of this announcement is to conclude agreements on the active ingredient "Ibuprofen (ATC code: M01AE01) dosage form: REK, RET, prolonged-release tablet, SL prolonged-release capsule" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ibuprofen (ATC-Code: M01AE01) Darreichungsform: SUE, SIRThe purpose of this announcement is to conclude agreements on the active ingredient "ibuprofen (ATC code: M01AE01) dosage form: SUE, SIR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Isosorbid dinitrat (ATC-Code: C01DA08) Darreichungsform: RED, REK, RETThe purpose of this announcement is to conclude agreements on the active ingredient "Isosorbide dinitrate (ATC code: C01DA08) dosage form: RED, REK, RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Isosorbid dinitrat (ATC-Code: C01DA08) Darreichungsform: SUT, TABThe purpose of this announcement is to conclude agreements on the active ingredient "Isosorbide dinitrate (ATC code: C01DA08) dosage form: SUT, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Isosorbid mononitrat (ATC-Code: C01DA14) Darreichungsform: RED, REK, RETThe purpose of this announcement is to conclude agreements on the active ingredient "Isosorbide mononitrate (ATC code: C01DA14) dosage form: RED, REK, RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Isosorbid mononitrat (ATC-Code: C01DA14) Darreichungsform: TABThe purpose of this announcement is to conclude agreements on the active ingredient "Isosorbide mononitrate (ATC code: C01DA14) dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ivermectin (ATC-Code: P02CF01) Darreichungsform: TABThe purpose of this announcement is to conclude agreements on the active ingredient "ivermectin (ATC code: P02CF01) dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Amoxicillin (ATC-Code: J01CA04) Darreichungsform: GSE, PSEThe purpose of this announcement is to conclude agreements on the active ingredient "amoxicillin (ATC code: J01CA04) dosage form: GSE, PSE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Metamizol (ATC-Code: N02BB02) Darreichungsform: AMP, ILO, INFThe purpose of this announcement is to conclude agreements on the active ingredient "metamizole (ATC code: N02BB02) dosage form: AMP, ILO, INF" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Methyldopa (ATC-Code: C02AB01) Darreichungsform: FTA, TABThe purpose of this announcement is to conclude agreements on the active ingredient "Methyldopa (ATC code: C02AB01) dosage form: FTA, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Metoclopramid (ATC-Code: A03FA01) Darreichungsform: LSE, TEI, LOEThe purpose of this announcement is to conclude agreements on the active ingredient "metoclopramide (ATC code: A03FA01) dosage form: LSE, TEI, LOE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Metoprolol succinat, Hydrochlorothiazid (ATC-Code: C07BB02) Darreichungsform: RETThe purpose of this announcement is to conclude agreements on the active ingredient "Metoprolol succinate, hydrochlorothiazide (ATC code: C07BB02) dosage form: RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Montelukast (ATC-Code: R03DC03) Darreichungsform: GRAThe purpose of this announcement is to conclude agreements on the active ingredient "Montelukast (ATC code: R03DC03) dosage form: GRA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Montelukast (ATC-Code: R03DC03) Darreichungsform: KTAThe purpose of this announcement is to conclude agreements on the active ingredient "Montelukast (ATC code: R03DC03) dosage form: KTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Morphin (ATC-Code: N02AA01) Darreichungsform: AMP, ILO, INFThe purpose of this announcement is to conclude agreements on the active ingredient "morphine (ATC code: N02AA01) dosage form: AMP, ILO, INF" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Mupirocin (ATC-Code: R01AX06) Darreichungsform: NSAThe purpose of this announcement is to conclude agreements on the active ingredient "Mupirocin (ATC code: R01AX06) dosage form: NSA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Natalizumab (ATC-Code: L04AA23) Darreichungsform: IFKThe purpose of this announcement is to conclude agreements on the active ingredient "natalizumab (ATC code: L04AA23) dosage form: IFK" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Octreotid (Depot) (ATC-Code: H01CB02) Darreichungsform: TRS, DFLThe purpose of this announcement is to conclude agreements on the active ingredient "Octreotide (Depot) (ATC code: H01CB02) dosage form: TRS, DFL" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Atazanavir (ATC-Code: J05AE08) Darreichungsform: HKPThe purpose of this announcement is to conclude agreements on the active ingredient "atazanavir (ATC code: J05AE08) dosage form: ICP" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Posaconazol (ATC-Code: J02AC04) Darreichungsform: SUEThe purpose of this announcement is to conclude agreements on the active ingredient "Posaconazole (ATC code: J02AC04) dosage form: SUE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Salbutamol (ATC-Code: R03AC02) Darreichungsform: LOV - FertiginhalatThe purpose of this announcement is to conclude agreements on the active ingredient "Salbutamol (ATC code: R03AC02) dosage form: LOV - ready-to-use inhalate" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Salmeterol (ATC-Code: R03AC12) Darreichungsform: DOSThe purpose of this announcement is to conclude agreements on the active ingredient "salmeterol (ATC code: R03AC12) dosage form: DOS" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Sapropterin (ATC-Code: A16AX07) Darreichungsform: PLE, TLEThe purpose of this announcement is to conclude agreements on the active ingredient "sapropterin (ATC code: A16AX07) dosage form: PLE, TLE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Teriflunomid (ATC-Code: L04AA31) Darreichungsform: FTAThe purpose of this announcement is to conclude agreements on the active ingredient "Teriflunomide (ATC code: L04AA31) dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Teriparatid (ATC-Code: H05AA02) Darreichungsform: ILOThe purpose of this announcement is to conclude agreements on the active ingredient "teriparatide (ATC code: H05AA02) dosage form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Xylometazolin (ATC-Code: R01AA07) Darreichungsform: EDP, NDS, NSG, NAG, NTR, NasenlösungThe purpose of this announcement is to conclude agreements on the active ingredient "Xylometazoline (ATC code: R01AA07) dosage form: EDP, NDS, NSG, NAG, NTR, nasal solution" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ranolazin (ATC-Code: C01EB18) Darreichungsform: RETThe purpose of this announcement is to conclude agreements on the active ingredient "Ranolazine (ATC code: C01EB18) dosage form: RET" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Fingolimod (ATC-Code: L04AA27) Darreichungsform: HKPThe purpose of this announcement is to conclude agreements on the active ingredient "fingolimod (ATC code: L04AA27) dosage form: ICP" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Ganirelix (ATC-Code: H01CC01) Darreichungsform: IFE, ILOThe purpose of this announcement is to conclude agreements on the active ingredient "Ganirelix (ATC code: H01CC01) dosage form: IFE, ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Betamethason (ATC-Code: D07AC01) Darreichungsform: CREThe purpose of this announcement is to conclude agreements on the active ingredient "betamethasone (ATC code: D07AC01) dosage form: CRE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Tocilizumab (ATC code: L04AC07)The purpose of this announcement is to conclude agreements on the active ingredient "tocilizumab (ATC code: L04AC07)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Rotigotin (ATC-Code: N04BC09) Darreichungsform: PFTThe purpose of this announcement is to conclude agreements on the active ingredient "Rotigotine (ATC code: N04BC09) dosage form: PFT" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Betamethason (ATC-Code: D07AC01) Darreichungsform: EMUThe purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) dosage form: EMU" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Betamethason (ATC-Code: D07AC01) Darreichungsform: LOEThe purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) dosage form: LOE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Betamethason (ATC-Code: D07AC01) Darreichungsform: SALThe purpose of this announcement is to conclude agreements on the active ingredient "Betamethasone (ATC code: D07AC01) dosage form: SAL" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.
Betamethasone, salicylic acid (ATC code: D07XC01) Dosage Form: SALThe purpose of this announcement is to conclude agreements on the active ingredient "betamethasone, salicylic acid (ATC code: D07XC01) dosage form: SAL" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:
a) Signed by hand (written form according to § 126 BGB) by mail or
b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-07@kbs.de sent to the KBS.
The earliest start date of the contract is 01.11.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.10.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.09.2025. In any case, the contracts will end on 31.10.2025.